| Literature DB >> 22123864 |
Meredith E K Calvert1, Graham D Wright, Fong Yew Leong, Keng-Hwee Chiam, Yinxiao Chen, Gregory Jedd, Mohan K Balasubramanian.
Abstract
In eukaryotes, cytokinesis is accomplished by an actomyosin-based contractile ring. Although in Caenorhabditis elegans embryos larger cells divide at a faster rate than smaller cells, it remains unknown whether a similar mode of scalability operates in other cells. We investigated cytokinesis in the filamentous fungus Neurospora crassa, which exhibits a wide range of hyphal circumferences. We found that N. crassa cells divide using an actomyosin ring and larger rings constricted faster than smaller rings. However, unlike in C. elegans, the total amount of myosin remained constant throughout constriction, and there was a size-dependent increase in the starting concentration of myosin in the ring. We predict that the increased number of ring-associated myosin motors in larger rings leads to the increased constriction rate. Accordingly, reduction or inhibition of ring-associated myosin slows down the rate of constriction. Because the mechanical characteristics of contractile rings are conserved, we predict that these findings will be relevant to actomyosin ring constriction in other cell types.Entities:
Mesh:
Substances:
Year: 2011 PMID: 22123864 PMCID: PMC3257563 DOI: 10.1083/jcb.201101055
Source DB: PubMed Journal: J Cell Biol ISSN: 0021-9525 Impact factor: 10.539
Figure 1.Range of hyphal diameters observed in White arrows indicate positions and diameters of septa. All images are to the same scale. Bar, 10 µm.
Conservation of actomyosin ring components among divergent eukaryotes
| Protein | |||
| Profilin | Cdc3 ( | Pfn-1 ( | S.p, C.e. NCU06397* |
| Myosin essential light chain | Cdc4 ( | ND | S.p. CU06617* |
| Tropomyosin | Cdc8 ( | Tmy-1 ( | S.p. NCU01204*, C.e. NCU01878 |
| F-BAR domain–containing protein | Cdc15 ( | ND | S.p. NCU10905 |
| Formin | Cdc12 ( | Cyk-1 ( | S.p., C.e. NCU01431* (SepA) |
| Myosin type II heavy chain | Myo2 ( | Nmy-2 ( | S.p., C.e. NCU00551 |
| Actin | Act1 ( | Act-1/3, Act-2, Act-3 ( | S.p., C.e. NCU04173*, NCU04247* |
| ADF/cofilin | Adf1 ( | Unc-60 ( | S.p., C.e. NCU01587 |
| IQGAP | Rng2 ( | Pes-7 ( | S.p., C.e. NCU03116* (ras-GAP) |
| UCS domain–containing protein | Rng3 ( | Unc-45 ( | S.p., C.e. NCU06821* (Cro1) |
| Myosin regulatory light chain | Rlc1 ( | Mlc-4 ( | S.p., C.e. NCU04120* (Calmodulin) |
| Septin | Spn1, Spn2, Spn3, Spn4 ( | Unc-59 ( | S.p., C.e. NCU08297* (Cdc3), NCU03515* (Cdc10), NCU02464* (septin-1), NCU03795* (Cdc12) |
| F-BAR domain–containing protein | Imp2 ( | ND | S.p. NCU10905 |
| Alpha actinin | Ain1 ( | Atn-1 ( | S.p., C.e. NCU06429 |
| Paxilin | Pxl1 ( | ND | S.p. NCU09812.3 |
Genes encoding proteins homologous to highly conserved actomyosin ring components in both S. pombe and C. elegans are represented within the N. crassa genome. S. pombe has been included here because many of the proteins involved in cytokinesis are best characterized in this model system. Asterisk indicates annotated genes. If the name given in the annotation differs from the name of the homologous protein, the given name is indicated in parentheses. ND indicates a homologous role in cytokinesis has not been characterized for this protein. S.p., S. pombe homologue; C.e., C. elegans homologue.
Figure 2.Characterization of Myosin II in (A) Schematic representation of N. crassa myo2 gene structure and the corresponding encoded protein domains (drawn to scale). The three coding exons (I, II, and III), two small introns, and 3′ UTR are indicated. SH3, SH3 domain; MH, myosin head (motor domain); MT, myosin tail. Numbering indicates the corresponding amino acid residues within the protein sequence. (B) Septa in a wild-type N. crassa strain. The wild-type FGSC#9719 strain was labeled with FM4-64 to visualize membranes and septa. White arrows indicate positions of septa. The image was created from 11 overlapping individual confocal images by merging and cropping in Adobe Photoshop. Bar, 50 µm. (C) Septation is defective in a heterokaryon knockout strain of the myosin II homologue, NCU00551. NCU00551 deleted heterokaryons were labeled with FM4-64 to visualize membranes and septa. The image was created from 12 overlapping individual confocal images by merging and cropping in Adobe Photoshop. Bar, 50 µm. (D) Myo2-GFP localized to a discreet region on the hyphal cortex, assembled into a contractile ring, and persisted at the ring throughout septation. The time is indicated in minutes; arrowhead indicates the region of preassembly accumulation. Bar, 5 µm. See also Video 1. (E) A kymograph showing the decrease in ring diameter over time within a representative hypha expressing Myo2-GFP (green) and membranes labeled with FM4-64 (red) and a merge of the two.
Figure 3.F-actin localization at the division site in (A) The actin-binding probe Lifeact-GFP accumulated along the hyphal cortex, assembled into a contractile ring, and persisted at the ring throughout septation. The time is indicated in minutes. Bar, 10 µm. See also Video 2. (B) Actomyosin ring constriction was observed using Lifeact-GFP (green), FM4-64 (red), and calcofluor (blue) to label actin, cell membrane, and cell wall, respectively. Image shows a transverse section of a representative cell during ring constriction. Bar, 5 µm. See also Video 3. (C) A kymograph showing the decrease in ring diameter over time within a representative hypha expressing Lifeact-GFP (green) and membranes labeled with FM4-64 (red) and a merge of the two.
Figure 4.Rate and duration of actomyosin ring constriction in (A) A graph showing the linear decrease in ring circumference calculated from image analysis of the Lifeact-GFP signal over time in a representative cell. The time points in red correspond to the constant phase of ring constriction; time points in blue show those during ring assembly and at the end of constriction, after the final pore size has been reached. The areas shaded blue were excluded for the calculation of constriction rate. (B) The rate of ring constriction is size dependent and larger rings constrict at a faster rate. Each data point represents the rate measured during the linear phase of constriction for individual rings of initial circumference 10–20 µm (blue), 20–40 µm (white), and > 40 µm (red); n = 98. R2 values and equations of the lines are indicated. (C) Average duration of constriction in cells with large (mean circumference = 45 µm; red, n = 21) and small (mean circumference = 15 µm; blue, n = 29) initial ring circumference. Each data point represents the mean ring circumference of cells within that size category at a given time during ring constriction. Error bars represent the standard deviation from the mean; n ≥ 10 measurements for each time point. The dotted line indicates the result predicted in large cells if the constriction rate were fully scalable with size, whereas the dashed line indicates that if constriction rate is completely nonscalable and size independent.
Figure 5.Quantitation of total amount and concentration of ring-associated F-actin and myosin II. (A) Total amount of Myo2-GFP (open circles; top, n = 59) and Lifeact-GFP (closed circles; bottom, n = 43) expressed in relative units of fluorescence intensity, as a function of hyphal circumference at start of constriction. R2 values and equations of the lines are indicated. Asterisk indicates a correlation coefficient where P < 0.001. (B) Concentration of Myo2-GFP (open circles; top, n = 59) and Lifeact-GFP (closed circles; bottom, n = 43) expressed in relative units of fluorescence intensity per confocal volume, as a function of hyphal circumference at start of constriction. R2 values and equations of the lines are indicated. Asterisk indicates a correlation coefficient where P < 0.001.
Figure 6.Concentration of ring-associated F-actin and myosin II during ring constriction. (A) Change in concentration of Myo2-GFP (red) and Lifeact-GFP (blue) during 3 min of ring constriction, expressed as change in fluorescence intensity. Data shown is mean of nine (Myo2-GFP) or five (Lifeact-GFP) independent experiments; error bars indicate the standard deviation from the mean. (B) Total amount of ring-associated Myo2-GFP at start (open symbols) and after 3 min of constriction (closed symbols). Each color represents a pair in which the larger ring (circles) has constricted to the same circumference as the smaller ring (triangles) at initiation of constriction. The dotted line connects corresponding pairs. The amount of Myo2-GFP is expressed in relative units of fluorescence intensity, as a function of hyphal circumference. (C) Distribution and intensity of Myo2-GFP in a representative pair of rings as described (green dataset) in B. Heat and profile map shows the relative intensity of Myo2-GFP at the start and after 3 min of constriction.
Figure 7.Turnover of myosin II and F-actin during ring constriction. (A) Fluorescence recovery after photobleaching (FRAP) of Myo2-GFP in a hypha with two rings in close proximity, rendered into a 3D image. The ring in the foreground was selectively photobleached while the second ring in the background remained unbleached. The time is indicated in minutes. Bar, 10 µm. See also Video 4. (B) Quantitation of FRAP of Myo2-GFP during actomyosin ring constriction. The whole ring was bleached and recovery was monitored as the change in intensity before and after bleaching, corrected for photobleaching resulting from the imaging. Data shown are the mean of 10 independent experiments, expressed in relative units of fluorescence intensity normalized to the corrected prebleach value; error bars represent the standard deviation from the mean. The half time for recovery is indicated on the graph. (C) Observation of Lifeact-GFP (green) and membranes labeled with FM4-64 (red) after inhibition of actin polymerization with DMSO alone (left) or 10 µM latrunculin A (right). Bar, 10 µm.
Figure 8.Inhibition of myosin II after treatment with blebbistatin. (A) Observation of Myo2-GFP (green) and membranes labeled with FM4-64 (red) after inhibition of myosin II with blebbistatin. MeOH alone as a control (top) and 1 mM blebbistatin (bottom). Bar, 10 µm. (B) Concentration of Myo2-GFP in constricting rings in medium sized cells (mean initial circumference = 25 µm) treated with MeOH alone (red, n = 27, top panel insert) or 100 µM blebbistatin (blue, n = 20, bottom panel insert) expressed in relative units of fluorescence intensity per confocal volume; error bars represent the standard deviation from the mean. Bar, 10 µm. Asterisk indicates statistical significance (unpaired t test; P < 0.0001). (C) Average rate of constriction in medium-sized cells (mean initial circumference = 25 µm) in cells treated with MeOH alone (red, n = 26) or 100 µM blebbistatin (blue, n = 22); error bars represent the standard deviation from the mean. Asterisk indicates statistical significance (unpaired t test, P < 0.0001). See also Video 5. (D) Average rate of constriction in medium-sized cells (mean initial circumference = 25 µm) of the Myo2-GFP homokaryon (red, n = 10), Myo2-GFP heterokaryon (blue, n = 11), and Lifeact-GFP (green, n = 38) strains; error bars represent the standard deviation from the mean. Asterisk indicates statistical significance (unpaired t test, P < 0.0001). (E) Concentration of Myo2-GFP in the Myo2-GFP homokaryon (red triangles, n = 25) and Myo2-GFP heterokaryon (blue circles, n = 22) expressed in relative units of fluorescence intensity per confocal volume, as a function of hyphal circumference.
Figure 9.A physical model for contractile ring dynamics. (A) Full scalability based on contractile unit hypothesis (ϕ = 1, λ = 0). (B) Super scalability due to scalable initial myosin density only (ϕ0 = 1, ζ = 0.5, λ = 0). (C) Size-dependent actin turnover leads to either full scalability (solid lines, ϕ0 = 1, ζ = 0) or super scalability (dashed lines, ϕ0 = 1, ζ > 0). (D) Size-independent actin turnover leads to partial scalability, as shown in experimental N. crassa data (symbols). Model (lines) uses fitted parameters (ζ = 0.3 ± 0.05, ϕ0 = 0.00085 ± 0.00015 s−1 [including uncertainty estimates], and λ = 0.052 ± 0.012 µm/s).
Sequences of oligonucleotides used in this paper
| Name | Sequence |
| LAF | 5′-GACTACTAGTATGGGCGTCGCCGACCTCATTAAGAAGTTCGAGTCTATTTCCAAGGAGGAGCCCGGGGACT-3′ |
| LAR | 5′-AGTCCCCGGGCTCCT-3′ |
| Myo21 | 5′-GGACATTGCTGCTGAGCG-3′ |
| Myo22 | 5′-CGGTGAGTTTAGGCTTTTTCATAATAAACCCCTTCGTCAG-3′ |
| Myo23 | 5′-TCGGCATGGACGAGCTGTACAAGGCTTTGAGGTGTCTATAG-3′ |
| Myo24 | 5′-TGAGCAAGACGTACACAG-3′ |
| Myo25 | 5′-CTGACGAAGGGGTTTATTATGAAAAAGCCTAAACTCACCG-3′ |
| Myo26 | 5′-CTATAGACACCTCAAAGCCTTGTACAGCTCGTCCATGCCGA-3′ |